Correspondence
Letter to ACMD on lisdexamphetamine, zoplicone and zaleplon
Letter from the Home Office to the Advisory Council on the Misuse of Drugs regarding the government's decision to classify these prescription medicines.
Documents
Details
Letter from Jeremy Browne to the chair of the ACMD, Les Iversen, outlines the decision to accept the council’s advice in full and to control lisdexamphetamine as a Class B, Schedule 2 drug and zoplicone and zaleplon as Class C and Schedule 4, Part 1 drugs.
Published 10 September 2013